CDSCO Bars Injectables From 'Cosmetic' Labelling, Targets GLP-1 Off-Label Use
India's drug regulator clarified injectables cannot be sold or marketed as cosmetics under the Drugs and Cosmetics Act, warning aesthetic clinics amid surging off-label GLP-1 weight-loss shots for pre-wedding and beauty use. The advisory tightens the line between licensed pharma and the booming medspa retail channel.
CDSCO clarified that injectable products cannot be labelled or sold as cosmetics under the Drugs and Cosmetics Act, warning aesthetic clinics and consumers amid rising off-label use of GLP-1 weight-loss injections for cosmetic and pre-wedding purposes in India.
Why this matters
Follows DCGI's directive that cosmetics are for beautifying not treatment, and a parallel crackdown on illegal sildenafil and tadalafil sales, signaling a coordinated push against the unregulated aesthetic-pharma overlap.
Retail-brand signals steady at 450 in the last 90 days, with regulatory enforcement emerging as a recurring driver.